Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | SVP OPS & PROD DEV | June 07, 2024 | June 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date June 07, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,616 |
Reported balance
After 2024-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-07 · Exercise / conversion · Acquired 7,250 · Balance 123,616 F1: The number of shares beneficially owned by the reporting person is amended in this Form 4 to correct an administrative error in a Form 4 filed on March 9, 2023, which misreported that 1,951 shares were withheld on March 7, 2023 to cover taxes on a vesting of shares on that date, when 1,591 shares were withheld. In correcting this administrative error, the number of shares beneficially owned by the reporting person reflects an increase of 360 shares. |
| Common StockSEC Table I · non-derivative | Direct | 128,916 |
Reported balance
After 2024-06-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-06-07 · Exercise / conversion · Acquired 5,300 · Balance 128,916 |
| Common StockSEC Table I · non-derivative | Direct | 117,829 |
Reported balance
After 2024-06-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-06-07 · Tax withholding · Disposed 11,087 · Balance 117,829 F2: The shares were sold in multiple trades at prices ranging from $67.64 to $68.10. The price reported above reflects the weighted average sales price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.51 · Expires 2027-03-30 | Direct | 0 |
Reported balance
After 2024-06-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-07 · Exercise / conversion · Disposed 7,250 · Balance 0 F3: 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.06 · Expires 2028-04-05 | Direct | 0 |
Reported balance
After 2024-06-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-07 · Exercise / conversion · Disposed 5,300 · Balance 0 F4: 25% of the total options vested on each of April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares beneficially owned by the reporting person is amended in this Form 4 to correct an administrative error in a Form 4 filed on March 9, 2023, which misreported that 1,951 shares were withheld on March 7, 2023 to cover taxes on a vesting of shares on that date, when 1,591 shares were withheld. In correcting this administrative error, the number of shares beneficially owned by the reporting person reflects an increase of 360 shares.
F2: The shares were sold in multiple trades at prices ranging from $67.64 to $68.10. The price reported above reflects the weighted average sales price.
F3: 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021.
F4: 25% of the total options vested on each of April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2024 Filed Jun 11, 2024 20:51 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option (right to buy) · Derivative | 5,300 | $57.06 Strike: $57.06 | $302,418.00 |
DisclosureSEC source: 0001579587-24-000013 · wk-form4_1718139096.xml · derivative · entry 5 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,300 shares Expires 2028-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the total options vested on each of April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:51 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option (right to buy) · Derivative | 7,250 | $49.51 Strike: $49.51 | $358,947.50 |
DisclosureSEC source: 0001579587-24-000013 · wk-form4_1718139096.xml · derivative · entry 4 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,250 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the total options vested on each of March 31, 2018, March 31, 2019, March 31, 2020, and March 31, 2021. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:51 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 11,087 | $67.70 | $750,589.90 |
DisclosureSEC source: 0001579587-24-000013 · wk-form4_1718139096.xml · nonDerivative · entry 3 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,829 F2 · price: The shares were sold in multiple trades at prices ranging from $67.64 to $68.10. The price reported above reflects the weighted average sales price. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:51 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 5,300 | $57.06 | $302,418.00 |
DisclosureSEC source: 0001579587-24-000013 · wk-form4_1718139096.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:51 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 7,250 | $49.51 | $358,947.50 |
DisclosureSEC source: 0001579587-24-000013 · wk-form4_1718139096.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The number of shares beneficially owned by the reporting person is amended in this Form 4 to correct an administrative error in a Form 4 filed on March 9, 2023, which misreported that 1,951 shares were withheld on March 7, 2023 to cover taxes on a vesting of shares on that date, when 1,591 shares were withheld. In correcting this administrative error, the number of shares beneficially owned by the reporting person reflects an increase of 360 shares. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 01:13 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,799 | $66.96 | $187,421.04 |
DisclosureSEC source: 0001579587-24-000011 · wk-form4_1712884382.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,006 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,137 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 23, 2024 Filed Mar 25, 2024 20:14 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 3,653 | $69.58 | $254,175.74 |
DisclosureSEC source: 0001579587-24-000009 · wk-form4_1711397661.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,805 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,010 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 02:42 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,034 | $66.71 | $135,688.14 |
DisclosureSEC source: 0001579587-24-000006 · wk-form4_1709865716.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,458 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,644 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 02:42 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 24,338 | $66.37 | $1,615,313.06 |
DisclosureSEC source: 0001579587-24-000006 · wk-form4_1709865716.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,492 F1 · price: The shares were sold in multiple trades at prices ranging from $66.00 to $66.75. The price reported above reflects the weighted average sales price. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:09 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,058 | $67.67 | $71,594.86 |
DisclosureSEC source: 0001579587-24-000004 · wk-form4_1709330942.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,830 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,256 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:47 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001579587-24-000002 · wk-form4_1708120015.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,888 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:47 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 10,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001579587-24-000002 · wk-form4_1708120015.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,178 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 14, 2024. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:17 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option (right to buy) · Derivative | 1,667 | $33.00 Strike: $33.00 | $55,011.00 |
DisclosureSEC source: 0001579587-23-000005 · wk-form4_1692994664.xml · derivative · entry 5 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires 2024-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the total options vested on each of April 1, 2015, April 1, 2016, April 1, 2017, and April 1, 2018. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:17 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $40.59 Strike: $40.59 | $152,212.50 |
DisclosureSEC source: 0001579587-23-000005 · wk-form4_1692994664.xml · derivative · entry 4 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2026-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the total options vested on each of April 7, 2017, April 7, 2018, April 7, 2019, and April 7, 2020. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:17 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 3,932 | $63.00 | $247,716.00 |
DisclosureSEC source: 0001579587-23-000005 · wk-form4_1692994664.xml · nonDerivative · entry 3 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,112 Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:17 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 1,667 | $33.00 | $55,011.00 |
DisclosureSEC source: 0001579587-23-000005 · wk-form4_1692994664.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 20:17 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Exercise / conversionCommon Stock | 3,750 | $40.59 | $152,212.50 |
DisclosureSEC source: 0001579587-23-000005 · wk-form4_1692994664.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:42 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,289 | $38.50 | $88,126.50 |
DisclosureSEC source: 0001104659-23-044634 · tm2312564-1_4seq1.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,627 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,137 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 28, 2023 Filed Mar 31, 2023 00:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 524 | $38.62 | $20,236.88 |
DisclosureSEC source: 0001104659-23-039340 · tm2311020-2_4seq1.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,206 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,712 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 23, 2023 Filed Mar 28, 2023 00:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,452 | $37.82 | $92,734.64 |
DisclosureSEC source: 0001104659-23-037251 · tm2310677-3_4seq1.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,730 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,010 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:36 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 509 | $44.23 | $22,513.07 |
DisclosureSEC source: 0001104659-23-030618 · tm239061-1_4seq1.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,182 Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:36 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,951 | $44.23 | $86,292.73 |
DisclosureSEC source: 0001104659-23-030618 · tm239061-1_4seq1.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,691 Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 8,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041737 · tm2311710-6_4seq1.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,916 F2 · kind: These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Read SEC document |
| February 28, 2023 Filed Apr 5, 2023 00:06 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 13,026 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-041737 · tm2311710-6_4seq1.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,232 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 28, 2023. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 01:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 5,172 | $37.79 | $195,463.84 |
DisclosureSEC source: 0001415889-22-008738 · form4-08162022_060804.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,642 F2 · price: The shares were sold in multiple trades at prices ranging from $37.70 to $38.00. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 01:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 12,894 | $37.04 | $477,605.36 |
DisclosureSEC source: 0001415889-22-008738 · form4-08162022_060804.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,814 F1 · price: The shares were sold in multiple trades at prices ranging from $37.01 to $37.295. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:35 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004408 · form4-04292022_030410.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,708 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 7, 2022. Read SEC document |
| April 10, 2022 Filed Apr 12, 2022 21:13 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,878 | $29.91 | $56,170.98 |
DisclosureSEC source: 0001415889-22-004022 · form4-04122022_020409.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,064 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,137 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 21:36 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 337 | $29.69 | $10,005.53 |
DisclosureSEC source: 0001415889-22-003968 · form4-04082022_020452.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,942 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,100 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 28, 2022 Filed Mar 30, 2022 20:13 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 524 | $28.17 | $14,761.08 |
DisclosureSEC source: 0001415889-22-003472 · form4-03302022_010359.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,279 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,712 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 00:49 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 19,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003394 · form4-03282022_050305.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,803 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 7, 2022. Read SEC document |
| March 23, 2022 Filed Mar 26, 2022 00:56 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 2,452 | $27.03 | $66,277.56 |
DisclosureSEC source: 0001415889-22-003382 · form4-03252022_050339.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,869 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 8,010 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 21:26 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 1,878 | $31.86 | $59,833.08 |
DisclosureSEC source: 0001415889-21-001981 · form4-04132021_020416.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,321 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,137 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| April 06, 2021 Filed Apr 8, 2021 00:29 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 337 | $33.69 | $11,353.53 |
DisclosureSEC source: 0001415889-21-001946 · form4-04072021_050439.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,199 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,100 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 00:57 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 278 | $36.14 | $10,046.92 |
DisclosureSEC source: 0001415889-21-001724 · form4-03312021_050326.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,536 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 907 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 29, 2021 Filed Apr 1, 2021 00:57 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 524 | $32.68 | $17,124.32 |
DisclosureSEC source: 0001415889-21-001724 · form4-03312021_050326.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,814 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,712 shares of restricted stock, the grant of which was previously reported. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:45 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 32,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001661 · form4-03252021_010339.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP OPS & PROD DEV 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,338 F1 · kind: Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of March 23, 2021. Read SEC document |
| April 10, 2020 Filed Apr 14, 2020 20:31 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 24,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-046392 · tm2015775d1_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,297 F1 · kind: The restricted stock vests in four equal annual installments on the first, second, third and fourth anniversaries of April 10, 2020. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 21:53 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 144 | $43.93 | $6,325.92 |
DisclosureSEC source: 0001104659-20-044728 · tm2015378d2_4.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,749 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 469 shares of restricted stock, which was previously reported. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 21:53 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 337 | $43.22 | $14,565.14 |
DisclosureSEC source: 0001104659-20-044728 · tm2015378d2_4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,893 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,100 shares of restricted stock, which was previously reported. Read SEC document |
| May 17, 2019 Filed May 20, 2019 20:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 8,907 | $70.67 | $629,457.69 |
DisclosureSEC source: 0001144204-19-027313 · tv522071_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,230 F1 · price: The shares were sold in multiple trades at prices ranging from $70.50 to $71.00. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2019 Filed May 15, 2019 20:32 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | SaleCommon Stock | 4,917 | $70.31 | $345,714.27 |
DisclosureSEC source: 0001144204-19-026614 · tv521699_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,137 F1 · price: The shares were sold in multiple trades at prices ranging from $70.00 to $70.50. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 115 | $68.60 | $7,889.00 |
DisclosureSEC source: 0001144204-19-020281 · tv519118_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,054 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 375 shares of restricted stock, which was previously reported. Read SEC document |
| April 07, 2019 Filed Apr 9, 2019 20:45 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 144 | $70.50 | $10,152.00 |
DisclosureSEC source: 0001144204-19-018901 · tv518454_form4.xml · nonDerivative · entry 2 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,169 F2 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 469 shares of restricted stock, which was previously reported. Read SEC document |
| April 06, 2019 Filed Apr 9, 2019 20:45 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 337 | $70.50 | $23,758.50 |
DisclosureSEC source: 0001144204-19-018901 · tv518454_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,313 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 1,100 shares of restricted stock, which was previously reported. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:46 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 278 | $70.54 | $19,610.12 |
DisclosureSEC source: 0001144204-19-017770 · tv517845_4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,650 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 906 shares of restricted stock, which was previously reported. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 8,285 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001144204-19-017412 · tv517661_4.xml · derivative · entry 2 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,285 Underlying: Common Stock · 8,285 shares Expires 2029-03-27 F1 · security: The restricted stock and stock options vest in four equal annual installments on the first, second, third and fourth anniversary of March 28, 2019. F1 · derivative.exercise_date: The restricted stock and stock options vest in four equal annual installments on the first, second, third and fourth anniversary of March 28, 2019. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-017412 · tv517661_4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,928 Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:01 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 253 | $61.88 | $15,655.64 |
DisclosureSEC source: 0001144204-18-030785 · tv494956_form4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,080 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 20:34 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | Tax withholdingCommon Stock | 115 | $60.21 | $6,924.15 |
DisclosureSEC source: 0001144204-18-021175 · tv491302_4.xml · nonDerivative · entry 1 Marken James G. · CIK 0001579587 · SVP Ops & Prod Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,333 F1 · kind: Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of restricted stock, which was previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.